WO2006016930A3 - Methods for treating hcv infection - Google Patents

Methods for treating hcv infection Download PDF

Info

Publication number
WO2006016930A3
WO2006016930A3 PCT/US2005/016927 US2005016927W WO2006016930A3 WO 2006016930 A3 WO2006016930 A3 WO 2006016930A3 US 2005016927 W US2005016927 W US 2005016927W WO 2006016930 A3 WO2006016930 A3 WO 2006016930A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
reducing
hcv
hcv infection
infection
Prior art date
Application number
PCT/US2005/016927
Other languages
French (fr)
Other versions
WO2006016930A2 (en
Inventor
Lawrence M Blatt
Original Assignee
Intermune Inc
Lawrence M Blatt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc, Lawrence M Blatt filed Critical Intermune Inc
Publication of WO2006016930A2 publication Critical patent/WO2006016930A2/en
Publication of WO2006016930A3 publication Critical patent/WO2006016930A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. The methods generally involve administering to the individual a Type II interferon receptor agonist alone or in combination with a direct antiviral drug.
PCT/US2005/016927 2004-05-14 2005-05-13 Methods for treating hcv infection WO2006016930A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57132204P 2004-05-14 2004-05-14
US60/571,322 2004-05-14

Publications (2)

Publication Number Publication Date
WO2006016930A2 WO2006016930A2 (en) 2006-02-16
WO2006016930A3 true WO2006016930A3 (en) 2006-08-03

Family

ID=35839691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016927 WO2006016930A2 (en) 2004-05-14 2005-05-13 Methods for treating hcv infection

Country Status (1)

Country Link
WO (1) WO2006016930A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299038B2 (en) 2000-05-23 2012-10-30 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
RU2005118421A (en) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-BRANCHED NUCLEOSIDES AND MUTATION FLAVIVIRIDAE
BRPI0516825A (en) * 2004-10-01 2008-09-23 Vertex Pharma hepatitis c virus protease ns3-ns4a inhibition (vhc)
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2061513B1 (en) * 2007-09-14 2011-08-10 Schering Corporation Method of treating hepatitis c patients
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
DK2583677T1 (en) 2011-10-21 2015-01-19 Abbvie Inc Methods for treatment of HCV comprising at least two direct-acting antiviral agents ribavirin, interferon but not
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
KR20150074051A (en) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP7129703B2 (en) 2016-04-28 2022-09-02 エモリー ユニバーシティー Alkyne-Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Associated Therewith

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRESE M. ET AL.: "Interferon-gamma Inhibits Replication of Subgenomic and Genomic Hepatitis C virus RNAs", HEPATOLOGY, vol. 35, no. 3, March 2002 (2002-03-01), pages 694 - 703, XP002999943 *
HULTGREN C. ET AL.: "The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses", J. GENE VIROL., vol. 79, no. 10, October 1998 (1998-10-01), pages 2381 - 2391, XP002999944 *
RICE C.M. ET AL.: "Hepatitis C virus-specific T lymphocyte responses", CURRENT OPINION IN IMMUNOLOGY, vol. 7, no. 4, August 1995 (1995-08-01), pages 532 - 538, XP002999945 *
SNELL N.: "Ribavirin-current status of a broad spectrum antiviral agent", EXPERT OPIN. PHARMACOTHER., vol. 2, no. 8, August 2001 (2001-08-01), pages 1317 - 1324 *
WANG Q.M. ET AL.: "Recent advances in prevention and treatment of hepatitis C virus infectious", PROG. DRUG RES., September 2001 (2001-09-01), pages 79 - 110 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299038B2 (en) 2000-05-23 2012-10-30 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus

Also Published As

Publication number Publication date
WO2006016930A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2006016930A3 (en) Methods for treating hcv infection
WO2005013917A3 (en) Combination therapy for treating alphavirus infection and liver fibrosis
Loustaud-Ratti et al. Ribavirin: Past, present and future
WO2005067454A3 (en) Combination therapy for treating hepatitis c virus infection
Pawlotsky et al. Antiviral action of ribavirin in chronic hepatitis C
Lee et al. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials
WO2010039801A3 (en) Methods of treating hepatitis c virus infection
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
WO2009039248A8 (en) Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
JP2008518943A5 (en)
WO2008082601A3 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
JP2002515453A5 (en)
WO2009061395A3 (en) Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
WO2005110455A3 (en) Combination therapy for treating hepatitis virus infection
WO2004110392A3 (en) Compositions and methods for treating coronavirus infection and sars
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
Buster et al. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos (t) ide analogues
WO2005016288A3 (en) Methods and compositions for treatment of viral diseases
WO2000018417A3 (en) Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
UA95299C2 (en) Prophylactic or therapeutic agent for viral disease caused by hepatitis c virus
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2010081095A3 (en) Methods and compositions for inhibiting hepatitis c virus replication
WO2008073864A8 (en) Novel combinations
Beckebaum et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase